# Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

> **NCT06557057** · — · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 66 (estimated)

## Conditions studied

- HER2-Positive Breast Carcinoma

## Interventions

- **OTHER:** Non-Interventional Study

## Key facts

- **NCT ID:** NCT06557057
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-16
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06557057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06557057, "Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06557057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*